Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?
- New: Listen to this Bulletin
- Pharma Ramps Up Google Ad Spend on Psychedelic Keywords
- ASCENT-IBO: ARPA-H’s Ibogaine Trial Funding Opportunity
- An Aside: UMiami Gifts Ibogaine IND to Government, Trump Says
- CHCS Report Previews Path to Medicaid Coverage for Psychedelic Therapies
- Turnbull Turns Back on Polymorph Patent Critiques
- At-Home Ketamine Co. Innerwell Shutters
- Other Headlines
Pharma Ramps Up Google Ad Spend on Psychedelic Keywords
Large pharmaceutical companies appear to be ramping up U.S. Google ad spend targeting psychedelics-related keywords, with the most common ads pointing to Johnson & Johnson’s Spravato webpage.
Searching for more generic terms like “psychedelic” returns results from J&J as well as at-home ketamine providers like Mindbloom and BetterU.
There are also more narrowly-targeted ads, with search terms like “COMP360” and “DT120”, which are late-stage psychedelic drug candidates sponsored by Compass Pathways and Definium Therapeutics, respectively, also returning ads for Spravato along with ads for products like Rexulti (Otsuka’s brexpiprazole product) and ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks